SATURDAY, OCTOBER 1, 2016

FDA approves latest Gardasil HPV vaccine

The FDA has approved Gardasil 9 HPV vaccine. | Contributed photo

The Food and Drug Administration recently approved Gardasil 9, which guards against nine strains of the human papillomavirus (HPV).

Several recent clinical trials indicate that Gardasil 9 is 97 percent effective in preventing people from contracting vaginal, vulvar and cervical cancers.

One of the studies included 13,000 subjects. The most common side effects included pain at the injection site, headaches, redness and swelling. The FDA has approved the vaccine for females ages 9-25 years old and males 9-15 years old.

Previous Gardasil vaccines only protected against five HPV strains and were limited to only female recipients. Merck Pharmaceuticals created the new vaccine, which protects against nine strains, amounting to 90 percent of anal, vulvar, vaginal and cervical cancers.

Despite these findings, the Center for the Biology of Chronic Disease (CBCD) continues to recommend natural HPV remedies, such as Gene-Eden-VIR or Novirin, over the vaccine.

Gene-Eden-VIR and Novirin contain natural dietary supplements that are antiviral, such as Camellia Sinesis extract (a trace element), selenium, Cinnamomum extract, quercetin and licorice extract.

PolyDNA, the company responsible for developing and patenting the natural treatments, extensively researched thousands of medical and scientific papers, journals and studies to find natural ingredients that safely and effectively protect against latent viruses.

As of today, Gene-Eden-VIR and Novirin are the only two natural products on the market with published clinical studies that support their efficacy.